Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials

BACKGROUND: Erenumab, a fully human monoclonal antibody that targets the calcitonin gene-related peptide receptor, has demonstrated efficacy and safety in the prevention of episodic and chronic migraine. There exists an unmet need to establish the safety of erenumab in older individuals, in view of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lampl, Christian, Kraus, Viktoria, Lehner, Katrina, Loop, Brett, Chehrenama, Mahan, Maczynska, Zofia, Ritter, Shannon, Klatt, Jan, Snellman, Josefin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386939/
https://www.ncbi.nlm.nih.gov/pubmed/35978286
http://dx.doi.org/10.1186/s10194-022-01470-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386939/
https://www.ncbi.nlm.nih.gov/pubmed/35978286
http://dx.doi.org/10.1186/s10194-022-01470-4

Ejemplares similares